Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 761–770 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 761
- Medicine slug
- insulin-detemir
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
0.1 L/kg
- Numeric value
- 0.1
- Unit
- L/kg
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d38d65c1-25bf-401d-9c7e-a2c3222da8af (opens source in a new tab)
Insulin Detemir label
Version not recorded · Effective date not recorded
Distribution Insulin detemir has an apparent volume of distribution of approximately 0.1 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82192527-99aa-4b53-8ce9-9173668d309c (opens source in a new tab)
Insulin Detemir label
Version not recorded · Effective date not recorded
Distribution Insulin detemir has an apparent volume of distribution of approximately 0.1 L/kg.
Projected row 762
- Medicine slug
- insulin-human
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 7
- Source count
- 3
- Agreement rate
- 0.666667
- Recorded readings
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b519bd83-038c-4ec5-a231-a51ec5cc291f (opens source in a new tab)
Insulin Human label
Version not recorded · Effective date not recorded
Excretion — After subcutaneous administration of HUMULIN R doses in the 0.05-0.4 unit/kg dose range, the median apparent half-life is approximately 1.5 hours (range: 40 minutes-7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81199e55-ade9-46de-a5a3-c0415acee403 (opens source in a new tab)
Insulin Human label
Version not recorded · Effective date not recorded
Excretion — After subcutaneous administration of HUMULIN R doses in the 0.05-0.4 unit/kg dose range, the median apparent half-life is approximately 1.5 hours (range: 40 minutes-7 hours).
4.4 hours
- Numeric value
- 4.4
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6edd793-440b-40c2-96b5-c16133b7a921 (opens source in a new tab)
Insulin Human label
Version not recorded · Effective date not recorded
In healthy subjects given subcutaneous doses of HUMULIN N (0.4 unit/kg), the mean apparent half-life was approximately 4.4 hours (range: 1-84 hours).
Projected row 763
- Medicine slug
- insulin-human
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
0.32 to 0.67 L/kg
- Numeric value
- 0.32
- Unit
- L/kg
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b519bd83-038c-4ec5-a231-a51ec5cc291f (opens source in a new tab)
Insulin Human label
Version not recorded · Effective date not recorded
Distribution — When HUMULIN R is administered intravenously at doses of 0.1 or 0.2 unit/kg, the mean volume of distribution ranges between 0.32 to 0.67 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81199e55-ade9-46de-a5a3-c0415acee403 (opens source in a new tab)
Insulin Human label
Version not recorded · Effective date not recorded
Distribution — When HUMULIN R is administered intravenously at doses of 0.1 or 0.2 unit/kg, the mean volume of distribution ranges between 0.32 to 0.67 L/kg.
Projected row 764
- Medicine slug
- insulin-lispro
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
55%
- Numeric value
- 55
- Unit
- %
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ee01d2e-3525-4aa9-8ec1-5fb0f63dd47c (opens source in a new tab)
Insulin lispro label
Version not recorded · Effective date not recorded
The absolute bioavailability after subcutaneous injection ranges from 55% to 77% with doses between 0.1 to 0.2 unit/kg, inclusive.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2be14cbb-197a-4da8-82c8-2443594e7f6f (opens source in a new tab)
Insulin lispro label
Version not recorded · Effective date not recorded
The absolute bioavailability after subcutaneous injection ranges from 55% to 77% with doses between 0.1 to 0.2 unit/kg, inclusive.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6b8ff07-d3e2-457f-8a38-b60de60adf75 (opens source in a new tab)
Insulin lispro label
Version not recorded · Effective date not recorded
The absolute bioavailability after subcutaneous injection ranges from 55% to 77% with doses between 0.1 to 0.2 unit/kg, inclusive.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51d3dc11-52b9-4296-a2f4-58c770d4448d (opens source in a new tab)
Insulin lispro label
Version not recorded · Effective date not recorded
The absolute bioavailability after subcutaneous injection ranges from 55% to 77% with doses between 0.1 to 0.2 unit/kg, inclusive.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97d5e596-aae1-42c9-ae89-c3780959c467 (opens source in a new tab)
Insulin lispro label
Version not recorded · Effective date not recorded
The absolute bioavailability after subcutaneous injection ranges from 55% to 77% with doses between 0.1 to 0.2 unit/kg, inclusive.
Projected row 765
- Medicine slug
- insulin-lispro-aabc
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
34 L
- Numeric value
- 34
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5a056e2-b568-4ca6-9ed8-79c010942d00 (opens source in a new tab)
Insulin Lispro-Aabc label
Version not recorded · Effective date not recorded
Figure 2 Distribution Following a 15 unit intravenous bolus injection of LYUMJEV in healthy subjects, the geometric mean (CV%) volume of distribution of insulin lispro-aabc (Vd) was 34 L (30%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:616daea1-0b79-4970-a141-6f99f2072f02 (opens source in a new tab)
Insulin Lispro-Aabc label
Version not recorded · Effective date not recorded
Figure 2 Distribution Following a 15 unit intravenous bolus injection of LYUMJEV in healthy subjects, the geometric mean (CV%) volume of distribution of insulin lispro-aabc (Vd) was 34 L (30%).
Projected row 766
- Medicine slug
- iodixanol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
2.1 hr
- Numeric value
- 2.1
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fe89ea2-04f7-46c5-9c35-220d8c144a95 (opens source in a new tab)
Iodixanol label
Version not recorded · Effective date not recorded
Elimination In 40 healthy, young male volunteers receiving a single intravenous administration of iodixanol in doses of 0.3 gram Iodine/kg to 1.2 gram Iodine/kg body weight, the elimination half-life was 2.1 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9d87b8c-7695-4c0f-8e81-000dedb5f66d (opens source in a new tab)
Iodixanol label
Version not recorded · Effective date not recorded
Elimination In 40 healthy, young male volunteers receiving a single intravenous administration of VISIPAQUE in doses of 0.3 to 1.2 gram Iodine/kg body weight, the elimination half-life was 2.1 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d964c13-88ad-43be-88d4-a3a7ea4d5b5e (opens source in a new tab)
Iodixanol label
Version not recorded · Effective date not recorded
Elimination In 40 healthy, young male volunteers receiving a single intravenous administration of VISIPAQUE in doses of 0.3 to 1.2 gram Iodine/kg body weight, the elimination half-life was 2.1 hr.
Projected row 767
- Medicine slug
- iodixanol
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
0.26 L/kg
- Numeric value
- 0.26
- Unit
- L/kg
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fe89ea2-04f7-46c5-9c35-220d8c144a95 (opens source in a new tab)
Iodixanol label
Version not recorded · Effective date not recorded
The volume of distribution in adults was 0.26 L/kg body weight, consistent with distribution to extracellular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9d87b8c-7695-4c0f-8e81-000dedb5f66d (opens source in a new tab)
Iodixanol label
Version not recorded · Effective date not recorded
The volume of distribution in adults was 0.26 L/kg body weight, consistent with distribution to extracellular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d964c13-88ad-43be-88d4-a3a7ea4d5b5e (opens source in a new tab)
Iodixanol label
Version not recorded · Effective date not recorded
The volume of distribution in adults was 0.26 L/kg body weight, consistent with distribution to extracellular space.
Projected row 768
- Medicine slug
- iohexol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
12.6 hours
- Numeric value
- 12.6
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9456ef-c45a-450d-9004-a684af2bcc59 (opens source in a new tab)
Iohexol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following the intravenous administration of iohexol (between 500 mg iodine/kg to 1,500 mg iodine/kg) to 16 adult subjects, apparent first-order terminal elimination half-life was 12.6 hours and total body clearance was 131 (98 to 165) mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:164b27b9-97ae-4279-896f-1c4afa583dd1 (opens source in a new tab)
Iohexol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following the intravenous administration of iohexol (between 500 mg iodine/kg to 1,500 mg iodine/kg) to 16 adult subjects, apparent first-order terminal elimination half-life was 12.6 hours and total body clearance was 131 (98 to 165) mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:508c42eb-f5e5-44f1-e063-6294a90a4d1f (opens source in a new tab)
Iohexol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following the intravenous administration of iohexol (between 500 mg iodine/kg to 1,500 mg iodine/kg) to 16 adult subjects, apparent first-order terminal elimination half-life was 12.6 hours and total body clearance was 131 (98 to 165) mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eee15ebe-d349-4497-acef-6abe7a8247fb (opens source in a new tab)
Iohexol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following the intravenous administration of iohexol (between 500 mg iodine/kg to 1,500 mg iodine/kg) to 16 adult subjects, apparent first-order terminal elimination half-life was 12.6 hours and total body clearance was 131 (98 to 165) mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5088be1d-a708-1cac-e063-6394a90a2aff (opens source in a new tab)
Iohexol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following the intravenous administration of iohexol (between 500 mg iodine/kg to 1,500 mg iodine/kg) to 16 adult subjects, apparent first-order terminal elimination half-life was 12.6 hours and total body clearance was 131 (98 to 165) mL/min.
Projected row 769
- Medicine slug
- iopamidol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae8c18c9-3e7d-4515-b980-120025a88fc1 (opens source in a new tab)
Iopamidol label
Version not recorded · Effective date not recorded
Elimination The plasma half-life is approximately 2 hours after intravascular administration; the half-life is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69e9ab05-88f8-45f9-8bc1-ed33ab1385f0 (opens source in a new tab)
Iopamidol label
Version not recorded · Effective date not recorded
Elimination The plasma half-life is approximately 2 hours; the half-life is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11e893d2-0183-4581-b908-c8b7302c7edb (opens source in a new tab)
Iopamidol label
Version not recorded · Effective date not recorded
Elimination The plasma half-life is approximately 2 hours; the half-life is not dose dependent .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:797a11d7-dcd4-43ff-311b-3b48a10da2f2 (opens source in a new tab)
Iopamidol label
Version not recorded · Effective date not recorded
Elimination The plasma half-life is approximately 2 hours after intravascular administration; the half-life is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b9e0d24-c6ca-4e22-9422-936e9d475eaa (opens source in a new tab)
Iopamidol label
Version not recorded · Effective date not recorded
Elimination The plasma half-life is approximately 2 hours; the half-life is not dose dependent .
Projected row 770
- Medicine slug
- ioversol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549d38db-d4ed-4708-8f76-7cdaa157063f (opens source in a new tab)
Ioversol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In 12 healthy volunteers (6 receiving 50 mL and 6 receiving 150 mL of OPTIRAY 320), elimination half-life was 1.5 hours for both doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cb6ca5f-b249-49b0-a9eb-8aa583da7c74 (opens source in a new tab)
Ioversol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Based on the blood clearance curves for 12 healthy volunteers (6 receiving 50 mL and 6 receiving 150 mL of OPTIRAY 320), the biological half-life was 1.5 hours for both doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd718d1c-f813-4114-a50d-c744ff7eb1bf (opens source in a new tab)
Ioversol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Based on the blood clearance curves for 12 healthy volunteers (6 receiving 50 mL and 6 receiving 150 mL of OPTIRAY 320), the biological half-life was 1.5 hours for both doses.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=760Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.